Resources
11 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/19/2023 (updated 4/11/2024)
Implementation IV grantees with tools and strategies
Posted 5/5/2021 (updated 4/10/2024)
We discussed the importance of engaging community influencers in your efforts to improve prevention, treatment, and recovery systems and services. We talked about how to identify and engage these key community stakeholders and why this strategic activity is vital to your consortium’s sustainability.
Posted 11/11/2021 (updated 4/3/2024)
In this session, a former RCORP-Planning, current RCORP-Implementation, and newly awarded RCORP-Psychostimulant grantee shared how it used multisectoral collaboration, lived experience, and second-chance employment to build a program from the ground up.
Posted 11/11/2021 (updated 4/3/2024)
Joined this panel of former RCORP-Planning grantees as they shared their lessons learned and how they hit the ground running as they completed Planning and embarked on Implementation. Heard from panelists who received Implementation funding as well as those who were able to move forward without dedicated Implementation funding.
Posted 8/4/2021 (updated 4/2/2024)
Posted 7/7/2021 (updated 4/2/2024)
In 2015, 33,091 persons in the United States died from an opioid-related drug overdose.The epidemic of opioid overdose deaths has led to expanding the use of naloxone in community settings by non–medically trained bystanders who are often people who use drugs (PWUD). Since 2013, illicitly manufactured fentanyl (IMF), fentanyl analogs, and other synthetic opioids have played an increasing role in overdose deaths in the United States. Illicitly manufactured fentanyl (IMF) prevalence has increased. However, there is uncertainty about naloxone dose(s) used by nonmedical bystanders to reverse opioid overdoses in the context of increasing IMF.
Posted 2/4/2020 (updated 3/28/2024)
How States are Responding to the Opioid Crisis: An Overview Webinar Presentation and Materials
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).